The Colorectal Cancer Alliance advises the public on the American Cancer Society’s updated guidelines for colorectal cancer screening. The organization reinforces the importance of starting the exam from the age of 45 for people at medium risk. Colorectal cancer has become the deadliest cancer in individuals under 50 years of age and the second most lethal cancer overall. Tracking makes it possible to prevent the disease or identify it early, when treatment has a greater chance of success.
The update released on May 27, 2026 incorporates new fecal and blood tests as alternatives in specific situations. Experts from the Alliance’s Screen Smart initiative analyzed the recommendations to clarify the differences between available methods. Not all tests are equally effective or covered by health plans.
Guidelines recommend starting screening at age 45
People at average risk should start screening at age 45. Those with a family history, symptoms, or genetic conditions need to evaluate options sooner with their doctor. Colonoscopy remains the preferred method because it detects and removes precancerous lesions.
Many patients opt for non-invasive tests performed at home. Positive results always require confirmatory colonoscopy. Insurance coverage varies depending on the type of exam and official recommendations.
- Colonoscopy detects and removes polyps, preferred by ACS guidelines and widely covered by insurance.
- Stool mt-sDNA tests, such as Cologuard Plus, detect 43% of precancerous lesions, done at home and covered.
- High-quality FIT tests identify 24% of precancerous lesions, annually, at home and covered.
- New multitarget mRNA stool tests detect 41.3% of precancerous lesions, included in guidelines but with limited coverage.
- Blood-based tests, such as Shield and Simple Screen, do not detect pre-cancer and are only useful when others are refused, with restricted coverage.
Blood tests come as a secondary option
Blood tests represent an addition to guidelines to increase adherence. They do not replace preferred methods because they have less sensitivity for precancerous lesions. Any altered result requires immediate follow-up colonoscopy.
The American Cancer Society focuses on informed choice between patient and doctor. Factors such as age, health history and personal preferences influence the decision. Continuous innovation seeks to overcome barriers to access to screening.
USPSTF maintains focus on testing with robust evidence
The Colorectal Cancer Alliance supports testing rated A or B by the U.S. Preventive Services Task Force. These assessments guarantee greater scientific evidence and broad coverage by private insurance. Blood and some stool tests have not yet received these classifications.
Richard Wender, the Alliance’s medical consultant, highlighted the need for advances to combat the rise in cases in young people. Education and awareness remain priorities to increase screening rates.
Tracking options vary in sensitivity and practicality
Colonoscopy offers a complete visual examination of the intestine. Stool tests analyze samples sent by mail. Blood tests require simple in-office collection.
Each method has different recommended ranges. Adhering to the chosen exam increases the chances of early detection. Survival exceeds 90% when cancer is found early.
Alliance encourages conversations with health professionals
Experts recommend discussing all available alternatives. The best test is the one that the patient performs consistently. Campaigns like Screen Smart provide personalized guidance.
Michael Sapienza, CEO of the Colorectal Cancer Alliance, recalled that current tools save lives. The organization provides free resources to assist in choosing and scheduling.
The website getscreened.org offers personalized recommendations to share with your doctor. Additional information about risk factors is available at colorectalcancer.org.
Advances seek to expand access to early diagnosis
Colorectal cancer affects millions annually around the world. In the United States, rates in young people are growing at a worrying rate. Updated guidelines respond to this scenario with more options.
Research continues to develop even more accurate and affordable tests. Partnerships between organizations strengthen awareness campaigns. Regular screening remains the main prevention strategy.
